Interestingly a 2007 paper by Shi Zhengli talks about working on binding of S Portein SL-CoV & SARS-CoV with ACE2 receptors and use of HIV based Pseudovirus with cell lines ACE2 receptors of Human, Civet & Horsehoe Bats 
Another 2009 research by Shi Zhengli on Different S Protein sequences in SL-CoV & SARS-CoV and testing its adaptability HIV1/BJ01 Pseudovirus. This was used on mice for testing.
Now a 2010 paper by Shi Zhengli again talks about using ACE2 Molecules from several Bat Species and tested their interaction with Human Sars-CoV Spike Protein using HIV Psuedotype. An HIV-1 Pseudovirus carrying SARS-CoV with BJ01 was prepared (Means Lab Created)
The above Research including the ones i mentioned in earlier thread i.e. 2010, 2013 & 2015 papers by Shi Zhengli establish that there was Research going in Wuhan Institute of Virology on how to make SARS-CoV more potent for entry into Human Cells and were working on S Protein.
They also used HIV-1 Psudeotype Virus made in lab to see effectiveness of S Protien to allowing th SARS Virus to invade human cells by testing on Mice first. As French Nobel laureate said there it is indeed true activation of S Protein with laces of HIV-1 is medical research.
The contention HIV is not part of COVID-19 holds no weight. It is part of scientific research at Wuhan Labs. Also the arguement that HIV genomes is there in many other viruses also cuts no ice given lethality of how S Protein of this invades Human Cells disabling immune system.
Now this Paper in February 2020 by Shi Zhengli, she discusses how Spike Protein in COVID-19 binds with ACE2 receptors with Human cells. Also emphasises that most potent SARS-CoV specific Anti Bodies fail to neutralise the binding of S Portein with ACE2 receptors in COVID-19.
Something which makes this virus, its S Protien more potent than earlier coronavirus. However it identifies that CR-3022 anti body had far more effect in stopping the binding the process which makes it likely candidate for therapeutic candidate for vaccines & treatment of COVID19
